Statin: New hope for preventing and delaying thyroid-associated ophthalmopathy?

VernacularTitle:他汀类药物：预防及延缓甲状腺相关性眼病的新希望？
Author: Xiaona HU ; Zhaohui LYU
From: Chinese Journal of Endocrinology and Metabolism 2021;37(1):83-86
CountryChina
Language:Chinese
Abstract: Thyroid-associated ophthalmopathy(TAO)is an organ-specific autoimmune disease. A series of symptoms related to it cause serious harm to the physical and mental health of patients, and then seriously affect their quality of life. However, there is stilly lack of specific treatment methods at present. Even after effective treatment, it is difficult to fully recover the appearance changes. Therefore, it is very important to avoid or reduce the risk factors associated with the occurrence and progress of TAO. Hypercholesterolemia, as one of the potential risk factors for the occurrence and progression of TAO, has been concerned by more clinical researchers. Recent studies have found that statins can significantly reduce the incidence of ophthalmopathy and the risk of ophthalmopathy progression in patients with Graves disease. Based on the inflammatory pathological mechanism of TAO, statins may become a new hope to prevent and delay the occurrence and progression of TAO.